Deutsche Biotech Innovativ AG Stock BOERSE DUESSELDORF

Deutsche Biotech Innovativ AG, formerly, Venetus Beteiligungen AG, is a Germany-based biotechnology company. The Company focuses on the identification of relevant biomarkers in the blood of affected patients and develops targeted therapies to prevent septic shock and inhibit tumour growth, as well as a small molecule drug for breast cancer prevention, Procizumab, focus on antibody-based therapy for the treatment of organ failure in patients with cardiogenic shock. Its product portfolio comprises various indicators, among others, for sepsis therapy (Adrecizumab), for breast cancer prevention (DB1RA) and for cancer therapy (AB2302). Its research and development activities are entirely conducted by project companies, in which the Company holds interest.